Early chronic kidney disease: Diagnosis, management and models of care

Nature Reviews Nephrology

Volumn 11, Issue 8, 2015, Pages 491-502

  Wouters, Olivier J ^a   O'Donoghue, Donal J ^b   Ritchie, James ^b   Kanavos, Panos G ^a   Narva, Andrew S ^c  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGE; CHRONIC KIDNEY DISEASE; CLINICAL CLASSIFICATION; CLINICAL PRACTICE; GLOMERULUS FILTRATION RATE; HUMAN; INTEGRATED HEALTH CARE SYSTEM; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY HEALTH CARE; SYSTEMATIC REVIEW (TOPIC); UNITED STATES; DISEASE COURSE; KIDNEY FAILURE, CHRONIC; RENAL INSUFFICIENCY, CHRONIC; THEORETICAL MODEL;

DISEASE PROGRESSION; HUMANS; KIDNEY FAILURE, CHRONIC; MODELS, THEORETICAL; RENAL INSUFFICIENCY, CHRONIC;

EID: 84938213660     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2015.85     Document Type: Review

References (163)

1. James M. T., Haemmelgarn B. R. & Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 376, 162-162 (2010
2. Sarnak M. J., et al. Kidney disease as a risk factor for development of cardiovascular disease-a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 108, 2154-2169 (2003
3. Chen R. A., Scott S., Mattern W. D., Mohini R. & Nissenson A. R. The case for disease management in chronic kidney disease. Dis. Manag. 9, 86-92 (2006
4. Jha V., et al. Chronic kidney disease: global dimension and perspectives. Lancet 382, 260-272 (2013
5. Atkins R. C. The epidemiology of chronic kidney disease. Kidney Int. Suppl. 94, S14-S18 (2005
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 3, 1-150 (2013
7. Levey A. S. & Coresh J. Chronic kidney disease. Lancet 379, 165-180 (2012
8. Haynes R., et al. Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP). Am. J. Kidney Dis. 64, 40-48 (2014
9. United States Renal Data System. USRDS 2014 annual data report [online], http://www.usrds.org/adr.aspx (2015
10. Aitken G. R., et al. Change in prevalence of chronic kidney disease in England over time: comparison of nationally representative cross-sectional surveys from 2003 to 2010. BMJ Open 4, e005480 (2014
11. De Vecchi A. F., Dratwa M. & Wioedemann M. E. Healthcare systems and end-stage renal disease (ESRD) therapies-an international review: costs and reimbursement/funding of ESRD therapies. Nephrol. Dial. Transplant. 14 (Suppl. 6), 31-41 (1999
12. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J. Int. Med.268, 456-467 (2010
13. Feehally J., et al. Early detection of chronic kidney disease. BMJ 337, a1618 (2008
14. Levin A. & Stevens P. E. Early detection of CKD: the benefits, limitations and effects on prognosis. Nat. Rev. Nephrol. 7, 446-457 (2011
15. Locatelli F., Del Vecchio L. & Pozzoni P. The importance of early detection of chronic kidney disease. Nephrol. Dial. Transplant. 17, 2-7 (2002
16. El Nahas A. M. & Bello A. K. Chronic kidney disease: the global challenge. Lancet 365, 331-340 (2005
17. National Kidney Foundation. KIDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am. J. Kidney Dis. 39, S1-S266 (2002
18. Zhang L., et al. Prevalence and factors associated with CKD: a population study from Beijing. Am. J. Kidney Dis. 51, 373-384 (2008
19. Singh A. K., et al. Epidemiology and risk factors of chronic kidney disease in India-results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol. 14, 114 (2013
20. Imai E., et al. Prevalence of chronic kidney disease in the Japanese general population. Clin. Exp. Nephrol. 16, 621-630 (2009
21. Kim S., et al. The prevalence of chronic kidney disease (CKD) and the associated factors to CKD in urban Korea: a population-based cross-sectional epidemiology study. J. Korean Med. Sci. 24 (Suppl. 1), S11-S21 (2009
22. Otero A., et al. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrologia 30, 78-86 (2010
23. Wen C. P., et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462,293 adults in Taiwan. Lancet 371, 2173-2182 (2008
24. Grams M. E., Chow E. K. H., Segev D. L. & Coresh J. Lifetime Incidence of CKD Stages 3-5 in the United States. Am. J. Kidney Dis. 62, 245-252 (2013
25. Mendu M. L., et al. The usefulness of diagnostic testing in the initial evaluation of chronic kidney disease. JAMA Intern. Med. 175, 853-856 (2015
26. National Institute for Health and Clinical Care Excellence. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care [online],www.nice.org.uk/CG182 (2014
27. Lindeman R. D., Tobin J. & Shock N. W. Longitudinal-studies on the rate of decline in renal function with age. J. Am. Geriatr. Soc. 33, 278-285 (1985
28. O'Hare A. M., et al. Age affects outcomes in chronic kidney disease. J. Am. Soc. Nephrol. 18, 2758-2765 (2007
29. Coresh J., et al. Prevalence of chronic kidney disease in the United States. JAMA 298, 2038-2047 (2007
30. Glassock R. J. & Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans. Am. Clin. Climatol. Assoc. 120, 419-428 (2009
31. Turin T. C., et al. Proteinuria and rate of change in kidney function in a community-based population. J. Am. Soc. Nephrol. 24, 1661-1667 (2013
32. Eriksen B. O. & Ingebretsen O. C. The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age. Kidney Int. 69, 375-382 (2006
33. Speizer F. E. & Tager I. B. Epidemiology of chronic mucus hypersecretion and obstructive airways disease. Epidemiol. Rev. 1, 124-142 (1979
34. Gansevoort R. T., et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 80, 93-104 (2011
35. Levey A. S., et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 80, 17-28 (2011
36. Fliser D., Zeier M., Nowack R. & Ritz E. Renal functional reserve in healthy elderly subjects. J. Am. Soc. Nephrol. 3, 1371-1377 (1993
37. Abdelhafiz A. H., Brown S. H., Bello A. & El Nahas M. Chronic kidney disease in older people: physiology, pathology or both?. Nephron Clin. Pract. 116, c19-c24 (2010
38. Jones R. Trends in elderly diagnoses: links with multi-morbidity. British J. Healthcare Manage. 19, 553-558 (2013
39. Orueta J. F., Nuno-Solinis R., Garcia-Alvarez A. & Alonso-Moran E. Prevalence of multimorbidity according to the deprivation level among the elderly in the Basque Country. BMC Public Health 13, 918 (2013
40. Marengoni A., et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res. Rev. 10, 430-439 (2011
41. Glassock R. J. & Winearls C. Diagnosing chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 19, 123-128 (2010
42. Glassock R. J. & Winearls C. Screening for CKD with eGFR: Doubts and dangers. Clin. J. Am. Soc. Nephrol. 3, 1563-1568 (2008
43. Stevens L. A., Coresh J., Greene T. & Levey A. S. Assessing kidney function-measured and estimated glomerular filtration rate. N. Engl. J. Med. 354, 2473-2483 (2006
44. Bauer C., Melamed M. L. & Hostetter T. H. Staging of chronic kidney disease: time for a course correction. J. Am. Soc. Nephrol. 19, 844-846 (2008
45. Tonelli M., et al. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann. Intern. Med. 154, 12-21 (2011
46. Lin J., Knight E. L., Hogan M. L. & Singh A. K. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J. Am. Soc. Nephrol. 14, 2573-2580 (2003
47. Rule A. D., et al. Measured and estimated GFR in healthy potential kidney donors. Am. J. Kidney Dis. 43, 112-119 (2004
48. Poggio E. D., Wang X., Greene T., Van Lente F. & Hall P. M. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J. Am. Soc. Nephrol. 16, 459-466 (2005
49. Stevens L. A., et al. Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. Am. J. Kidney Dis. 50, 21-35 (2007
50. Murata K., et al. Relative performance of the MDRD and CKD-EPI equations for estimating glomerular filtration rate among patients with varied clinical presentations. Clin. J. Am. Soc. Nephrol. 6, 1963-1972 (2011
51. Levey A. S., et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604-612 (2009
52. Stevens L. A., et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J. Am. Soc. Nephrol. 18, 2749-2757 (2007
53. Hoffmann A., Nimtz M. & Conradt H. S. Molecular characterization of beta-trace protein in human serum and urine: a potential diagnostic marker for renal diseases. Glycobiology 7, 499-506 (1997
54. Stevens L. A., et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD. Am. J. Kidney Dis. 51, 395-406 (2008
55. Kilbride H. S., et al. Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly. Am. J. Kidney Dis. 61, 57-66 (2013
56. Fan L., et al. Comparing GFR estimating equations using cystatin C and creatinine in elderly individuals. J. Am. Soc. Nephrol. (2014
57. Schaeffner E. S., et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann. Intern. Med. 157, 471-481 (2012
58. Inker L. A., et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N. Engl. J. Med. 367, 20-29 (2012
59. Inker L. A., et al. Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values. Am. J. Kidney Dis. 58, 682-684 (2011
60. Saydah S. H., et al. Albuminuria prevalence in first morning void compared with previous random urine from adults in the National Health and Nutrition Examination Survey, 2009-2010 Clin. Chem. 59, 675-683 (2013
61. Naresh C. N., Hayen A., Weening A., Craig J. C. & Chadban S. J. Day to day variability in spot urine albumin-creatinine ratio. Am. J. Kidney Dis. 62, 1095-1101 (2013
62. Bakker S. J., Gansevoort R. T. & De Zeeuw D. Albuminuria: what can we expect from the determination of nonimmunoreactive albumin?. Curr. Hypertens. Rep. 11, 111-117 (2009
63. Witte E. C., et al. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J. Am. Soc. Nephrol. 20, 436-443 (2009
64. Brinkman J. W., et al. Falsely low urinary albumin concentrations after prolonged frozen storage of urine samples. Clin. Chem. 51, 2181-2183 (2005
65. Warram J. H., Gearin G., Laffel L. & Krolewski A. S. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio J. Am. Soc. Nephrol. 7, 930-937 (1996
66. Long D. A., et al. Albuminuria is associated with too few glomeruli and too much testosterone. Kidney Int. 83, 1118-1129 (2013
67. Lambers Heerspink H. J., et al. Albuminuria assessed from first morning void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am. J. Epidemiol. 168, 897-905 (2008
68. Hallan S. I., et al. Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J. Am. Soc. Nephrol. 20, 1069-1077 (2009
69. Tangri N., et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 305, 1553-1559 (2011
70. Tonelli M., et al. Chronic kidney disease and mortality risk: A systematic review. J. Am. Soc. Nephrol. 17, 2034-2047 (2006
71. Sehestedt T., et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur. Heart J. 31, 883-891 (2010
72. Jones-Burton C., et al. An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am. J. Nephrol. 26, 268-275 (2006
73. Smyth A., et al. The relationship between estimated sodium and potassium excretion and subsequent renal outcomes. Kidney Int. 86, 1205-1212 (2014
74. McMahon E. J., et al. A randomized trial of dietary sodium restriction in CKD. J. Am. Soc. Nephrol. 24, 2096-2103 (2013
75. Fink H. A., et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the US Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann. Intern. Med. 156, 570-581 (2012
76. Qaseem A., et al. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 159, 835-847 (2013
77. American Society of Nephrology. ASN emphasizes need for early detection of kidney disease, a silent killer [online], http://www.asn-online.org/news/2013/asn-comm-acp-screening-response-102213-r12.pdf (2013
78. Komenda P., et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am. J. Kidney Dis. 63, 789-797 (2014
79. Menzin J., et al. A review of the costs and cost effectiveness of interventions in chronic kidney disease implications for policy. Pharmacoeconomics 29, 839-861 (2011
80. Morales E., Valero M. A., Leon M., Hernandez E. & Praga M. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am. J. Kidney Dis. 41, 319-327 (2003
81. Saiki A., et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int. J. Obes. (Lond.) 29, 1115-1120 (2005
82. Solerte S. B., Fioravanti M., Schifino N. & Ferrari E. Effects of diet-therapy on urinary protein excretion albuminuria and renal haemodynamic function in obese diabetic patients with overt nephropathy. Int. J. Obes. 13, 203-211 (1989
83. Navaneethan S. D., et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 4, 1565-1574 (2009
84. Heiwe S. & Jacobson S. H. Exercise training for adults with chronic kidney disease. Cochrane Database Syst. Rev. Issue 10. Art. No.: CD003236. http://dx.doi.org/10.1002/14651858.CD003236.pub2
85. Robinson-Cohen C., et al. Physical activity and change in estimated GFR among persons with CKD. J. Am. Soc. Nephrol. 25, 399-406 (2014
86. Robinson-Cohen C., et al. Physical activity and rapid decline in kidney function among older adults. Arch. Intern. Med. 169, 2116-2123 (2009
87. Sawicki P. T., et al. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 17, 126-131 (1994
88. Chase H. P., et al. Cigarette-smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 265, 614-617 (1991
89. Schiffl H., Lang S. M. & Fischer R. Stopping smoking slows accelerated progression of renal failure in primary renal disease. J. Nephrol. 15, 270-274 (2002
90. Dalrymple L. S., et al. Chronic kidney disease and the risk of end-stage renal disease versus death. J. Gen. Intern. Med. 26, 379-385 (2011
91. Go A. S., Chertow G. M., Fan D. J., McCulloch C. E. & Hsu C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296-1305 (2004
92. Taal M. W. Arterial stiffness in chronic kidney disease: an update. Curr. Opin. Nephrol. Hypertens. 23, 169-173 (2014
93. Upadhyay A., et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann. Intern. Med. 157, 251-262 (2012
94. Palmer S. C., et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst. Rev. Issue 5. Art. No.: CD007784 http://dx.doi.org/10.1002/14651858.CD007784.pub2
95. Tonelli M., et al. Association between LDL C and risk of myocardial infarction in CKD. J. Am. Soc. Nephrol. 24, 979-986 (2013
96. Upadhyay A., Earley A., Haynes S. M. & Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann. Intern. Med. 154, 541-548 (2011
97. Ruggenenti P., et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 352, 1252-1256 (1998
98. Brenner B. M., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001
99. Rodby R. A., et al. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol. Dial. Transplant. 15, 487-497 (2000
100. Sharma P., et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst. Rev. Issue 10. Art. No.: CD007751 http://dx.doi.org/10.1002/14651858.CD007751.pub2
101. Jager K. J. & van Dijk P. C. W. Has the rise in the incidence of renal replacement therapy in developed countries come to an end?. Nephrol. Dial. Transplant. 22, 678-680 (2007
102. Vassalotti J. A., Gracz-Weinstein L., Gannon M. R. & Brown W. W. Targeted screening and treatment of chronic kidney disease: lessons learned from the kidney early evaluation program. Dis. Manag. Health Out. 14, 341-352 (2006
103. Katz I. J., Gerntholtz T. E., van Deventer M., Schneider H. & Naicker S. Is there a need for early detection programmes for chronic kidney disease?. Clin. Nephrol. 74, S113-S118 (2010
104. Lash J. P., et al. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin. J. Am. Soc. Nephrol. 4, 1302-1311 (2009
105. Feldman H. I., et al. The Chronic Renal Insufficiency Cohort (CRIC) study: design and methods. J. Am. Soc. Nephrol. 14, S148-S153 (2003
106. Kronenberg F. Emerging risk factors and markers of chronic kidney disease progression. Nat. Rev. Nephrol. 5, 677-689 (2009
107. Johnson E. S., Smith D. H., Thorp M. L., Yang X. H. & Juhaeri J. Predicting the risk of end-stage renal disease in the population-based setting: a retrospective case-control study. BMC Nephrol. 12, 17 (2011
108. Johnson E. S., Thorp M. L., Platt R. W. & Smith D. H. Predicting the risk of dialysis and transplant among patients with CKD: a retrospective cohort study. Am. J. Kid. Dis. 52, 653-660 (2008
109. Levin A., Djurdjev O., Beaulieu M. & Er L. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am. J. Kid. Dis. 52, 661-671 (2008
110. McClellan W. M. & Flanders W. D. Risk factors for progressive chronic kidney disease. J. Am. Soc. Nephrol. 14 (Suppl. 2), S65-S70 (2003
111. Peralta C. A., et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin to creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 305, 1545-1552 (2011
112. Mahmoodi B. K., et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 380, 1649-1661 (2012
113. Fox C. S., et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 380, 1662-1673 (2012
114. Rose G. Sick individuals and sick populations. Int. J. Epidemiol. 30, 427-432 (2001
115. Leoncini G., et al. Global risk stratification in primary hypertension: the role of the kidney. J. Hypertens. 26, 427-432 (2008
116. Perkins R. M., et al. GFR Decline and Mortality Risk among Patients with Chronic Kidney Disease. Clin. J. Am. Soc. Nephrol. 6, 1879-1886 (2011
117. Saweirs W. W. M. & Goddard J. What are the best treatments for early chronic kidney disease?. A background paper prepared for the UK consensus conference on early chronic kidney disease. Nephrol. Dial. Transplant. 22, 31-38 (2007
118. Loud F. & Gallagher H. Kidney health: delivering excellence. Kidney Health Report 1-52 (2013
119. Shahinian V. B. & Saran R. The role of primary care in the management of the chronic kidney disease population. Adv. Chronic Kidney Dis. 17, 246-253 (2010
120. Levin A. The need for optimal and coordinated management of CKD. Kidney Int. 68, 7-10 (2005
121. Bodenheimer T., Wagner E. H. & Grumbach K. Improving primary care for patients with chronic illness. JAMA 288, 1775-1779 (2002
122. Bodenheimer T., Wagner E. H. & Grumbach K. Improving primary care for patients with chronic illness-the chronic care model, part 2. JAMA 288, 1909-1914 (2002
123. Wagner E. H. Chronic disease management: what will it take to improve care for chronic illness?. Eff. Clin. Pract. 1, 2-4 (1998
124. Wagner E. H., Austin B. T. & VonKorff M. Organizing care for patients with chronic illness. Milbank Q. 74, 511-544 (1996
125. Hajjar I., Kotchen J. M. & Kotchen T. A. Hypertension: Trends in prevalence, incidence, and control. Annu. Rev. Public Health 27, 465-490 (2006
126. Danaei G., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378, 31-40 (2011
127. Finucane M. M., et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377, 557-567 (2011
128. Venkatachalam M. A., et al. Acute kidney injury: a springboard for progression in chronic kidney disease. Am. J. Physiol. Renal Physiol. 298, F1078-F1094 (2010
129. Chawla L. S. & Kimmel P. L. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int. 82, 516-524 (2012
130. Rewa O. & Bagshaw S. M. Acute kidney injury-epidemiology, outcomes and economics. Nat. Rev. Nephrol. 10, 193-207 (2014
131. Lea J. P., McClellan W. M., Melcher C., Gladstone E. & Hostetter T. CKD risk factors reported by primary care physicians: do guidelines make a difference?. Am. J. Kidney Dis. 47, 72-77 (2006
132. Boulware L. E., Troll M. U., Jaar B. G., Myers D. I. & Powe N. R. Identification and referral of patients with progressive CKD: a national study. Am. J. Kidney Dis. 48, 192-204 (2006
133. Charles R. F., et al. Clinical testing patterns and cost implications of variation in the evaluation of CKD among US physicians. Am. J. Kidney Dis. 54, 227-237 (2009
134. Fox C. H., Brooks A., Zayas L. E., McClellan W. & Murray B. Primary care physicians' knowledge and practice patterns in the treatment of chronic kidney disease: an Upstate New York Practice-based Research Network (UNYNET) study. J. Am. Board Fam. Med. 19, 54-61 (2006
135. Allen A. S., et al. Primary Care Management of Chronic Kidney Disease. J. Gen. Intern. Med. 26, 386-392 (2011
136. Razavian M., et al. Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). Nephrol. Dial. Transplant. 27, 1396-1402 (2012
137. Winkelmayer W. C., et al. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am. J. Kidney Dis. 46, 1080-1087 (2005
138. Minutolo R., et al. Management of hypertension in patients with CKD: Differences between primary and tertiary care settings. Am. J. Kidney Dis. 46, 18-25 (2005
139. Ravera M., et al. CKD awareness and blood pressure control in the primary care hypertensive population. Am. J. Kidney Dis. 57, 71-77 (2011
140. Ravera M., et al. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective. Nephrol. Dial Transplant. 24, 1528-1533 (2009
141. Israni R. K., Shea J. A., Joffe M. M. & Feldman H. I. Physician characteristics and knowledge of CKD management. Am. J. Kidney Dis. 54, 238-247 (2009
142. Black C., et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol. Assess. 14, 1-184 (2010
143. Crinson I., Gallagher H., Thomas N. & De Lusignan S. How ready is general practice to improve quality in chronic kidney disease?. A diagnostic analysis. Br. J. Gen. Pract. 60, 403-409 (2010
144. Jain P., Calvert M., Cockwell P. & McManus R. J. The need for improved identification and accurate classification of stages 3-5 chronic kidney disease in primary care: retrospective cohort study. PLoS ONE 9, e100831 (2014
145. Stevens P. E., Levin A. & Global K. D. I. Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline. Ann. Intern. Med. 158, 825-830 (2013
146. Narva A. S. Reducing the burden of chronic kidney disease among American Indians. Adv. Chronic Kidney Dis. 15, 168-173 (2008
147. Narva A. S. & Sequist T. D. Reducing health disparities in American Indians with chronic kidney disease. Semin. Nephrol. 30, 19-25 (2010
148. Sequist T. D., Cullen T. & Acton K. J. Indian health service innovations have helped reduce health disparities affecting american Indian and Alaska native people. Health Aff. (Millwood) 30, 1965-1973 (2011
149. Patel T. G., Pogach L. M. & Barth R. H. CKD screening and management in the Veterans Health Administration: the impact of system organization and an innovative electronic record. Am. J. Kidney Dis. 53 (Suppl. 3), S78-S85 (2009
150. Lee B., et al. Effects of proactive population-based nephrologist oversight on progression of chronic kidney disease: a retrospective control analysis. BMC Health Serv. Res. 12, 252 (2012
151. Rutkowski M., et al. Implementing KDOQI CKD Definition and Staging Guidelines in Southern California Kaiser Permanente. Am. J. Kidney Dis. 53 (Suppl. 3), S86-S99 (2009
152. Stevens P. E., et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 72, 92-99 (2007
153. Rayner H. C., et al. Does community-wide chronic kidney disease management improve patient outcomes?. Nephrol. Dial. Transplant. 29, 644-649 (2014
154. Richards N., et al. Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes. Nephrol. Dial. Transplant. 23, 549-555 (2008
155. Gaede P., Lund-Andersen H., Parving H. H. & Paedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358, 580-591 (2008
156. Hoy W. E., Baker P. R., Kelly A. M. & Wang Z. Reducing premature death and renal failure in Australian aboriginals. A community-based cardiovascular and renal protective programme. Med. J. Aust. 172, 473-478 (2000
157. Hirsch G., Homer J., Evans E. & Zielinski A. A system dynamics model for planning cardiovascular disease interventions. Am. J. Public Health 100, 616-622 (2010
158. Homer J. B. & Hirsch G. B. System dynamics modeling for public health: background and opportunities. Am. J. Public Health 96, 452-458 (2006
159. Ness R. B., Koopman J. S. & Roberts M. S. From the American College of Epidemiology Annual Meeting 2006-causal system modeling in chronic disease epidemiology: a proposal. Ann. Epidemiol. 17, 564-568 (2007
160. Zhou H., et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care 28, 2856-2863 (2005
161. Hallan S. I., et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J. Am. Soc. Nephrol. 17, 2275-2284 (2006
162. Jesky M., Lambert A., Burden A. C. & Cockwell P. The impact of chronic kidney disease and cardiovascular comorbidity on mortality in a multiethnic population: a retrospective cohort study. BMJ Open 3, e003458 (2013
163. Fassett R. G., et al. Biomarkers in chronic kidney disease: a review. Kidney Int 80, 806-821 (2011